The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things

Table 1 miRNAs and drug resistance in HCC

miRNA	Expression	Target	Drug	References
miR-32-5p	Upregulated	PTEN and PI3K/Akt	Multidrug	[40]
miR-106b-5p	Upregulated	BTG3/Bcl-xL/p27 axis	SOR	[59]
miR-30a-5p	Upregulated	CLCF1/PI3K/AKT axis	SOR	[60]
miR-126-3p	Upregulated	SPRED1	SOR	[64]
miR-10b-3p	Upregulated	Cyclin E1	SOR	[169]
miR-25	Downregulated	FBXW7	SOR	[58]
miR-124-3p.1	Downregulated	FOXO3a	SOR	[62]
miR-138–1-3p	Upregulated	PAK5	SOR	[57]
miR-15a-5p	Upregulated	eIF4E	Pirarubicin	[170]
miR-4461	Upregulated	SIRT1	Cisplatin	[171]
miR-27a-3p	Downregulated	PI3K/Akt	Cisplatin	[75]
miR-651-3p	Upregulated	ATG3	Cisplatin	[76]
miR-138-5p	Upregulated	EZH2	Cisplatin	[78]
miR-9	Upregulated	EIF5A2	Cisplatin	[172]
miR-610	Downregulated	HDGF	Cisplatin	[80]
miR-21-5p	Upregulated	FASLG	Cisplatin	[81]
miR-125b	Downregulated	EVA1A	OXA	[84]
miR-122	Downregulated	Wnt/β-catenin	OXA	[85]
miR-135a	Upregulated	VAMP2	DOX	[90, 91]
miR-26b	Downregulated	USP9X	DOX	[92]
miR-145	Upregulated	TLR4	5-FU	[111]

ISSN: 1479-5876